What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?

Urology

Volumn 62, Issue 3, 2003, Pages 492-496

  DeWitt, K D ^b   Sandler, H M ^b   Weinberg, V ^b   McLaughlin, P W ^b   Roach III, Mack ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGANIZATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; STATISTICAL ANALYSIS;

EID: 0042233786     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00460-6     Document Type: Article

References (22)

1. Kaplan I.D., Cox R.S., Bagshaw M.A. Prostate specific antigen after external beam radiotherapy for prostatic cancer followup . J Urol. 149:1993;519-522.
2. Kuban D.A., el-Mahdi A.M., Schellhammer P.F. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;307-316.
3. Pisansky T.M., Cha S.S., Earle J.D., et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 11:1993;2158-2166.
4. Zagars G.K. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am. 20:1993;737-747.
5. Zietman A.L., Coen J.J., Shipley W.U., et al. Radical radiation therapy in the management of prostatic adenocarcinoma the initial prostate specific antigen value as a predictor of treatment outcome . J Urol. 151:1994;640-645.
6. Perez C.A., Michalski J.M., Lockett M.A. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation comparison of American Society for Therapeutic Radiology and Oncology consensus or 1 ng/mL as endpoint . Int J Radiat Oncol Biol Phys. 49:2001;1287-1296.
7. Critz F.A., Levinson A.K., Williams W.H., et al. Prostate-specific antigen nadir the optimum level after irradiation for prostate cancer . J Clin Oncol. 14:1996;2893-2900.
8. Critz F.A., Levinson K., Williams W.H., et al. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology. 49:1997;668-672.
9. Critz F.A., Levinson A.K., Williams W.H., et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology. 49:1997;322-326.
10. Critz F.A., Williams W.H., Holladay C.T., et al. Post-treatment PSA or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology. 54:1999;968-971.
11. Hanks G.E., Lee W.R., Schultheiss T.E. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol. 154:(2 Pt 1):1995;456-459.
12. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. An analysis of clinical and treatment related prognostic factors on outcome using biochemical control as an end-point in patients with prostate cancer treated with external beam irradiation. Radiother Oncol. 44:1997;223-228.
13. Hanlon A. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 53:2002;297-303.
14. Lee W.R., Hanlon A.L., Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer the relationship between nadir level and disease-free survival . J Urol. 156:(2 Pt 1):1996;450-453.
15. Roach M. III, Lu J., Pilepich M.V., et al. Predicting long-term survival and the need for hormonal therapy a meta-analysis of RTOG prostate cancer trials . Int J Radiat Oncol Biol Phys. 47:2000;617-627.
16. Panel ASTRO Consensus Statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035-1041, 1997.
17. Roach M, Weinberg V, McLaughlin P, et al: Serum prostate specific antigen (PSA) and survival following external beam radiotherapy of the prostate. Urology 61: 730-735, 2003.
18. von Eschenbach A., Ho R., Murphy G.P., et al. American Cancer Society guidelines for the early detection of prostate cancer update, June 10, 1997 . Cancer. 80:1997;1805-1807.
19. Russell K.J., Dunatov C., Hafermann M.D., et al. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol. 146:1991;1046-1052.
20. Zagars G.K. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol. 152:(5 Pt 2):1994;1786-1791.
21. Geist R.W. Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. Urology. 45:1995;1016-1021.
22. Zietman A.L., Tibbs M.K., Dallow K.C., et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 40:1996;159-162.